Cargando…
Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
BACKGROUND: Patients with borderline resectable pancreatic cancer (BRPC) have poor prognosis with upfront surgery. METHODS: This was a single-arm Phase 2 trial for clinical and biomarker analysis. The primary endpoint is 1-year progression-free survival (PFS) rate. Patients received 8 cycles of neoa...
Autores principales: | Yoo, Changhoon, Lee, Sang Soo, Song, Ki Byung, Jeong, Jae Ho, Hyung, Jaewon, Park, Do Hyun, Song, Tae Jun, Seo, Dong Wan, Lee, Sung Koo, Kim, Myung-Hwan, Lee, Seung Soo, Kim, Jin Hee, Jin, Hyung-seung, Park, Jin-hong, Hwang, Dae Wook, Lee, Jae Hoon, Lee, Woohyung, Chang, Heung-Moon, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Kim, Song Cheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403346/ https://www.ncbi.nlm.nih.gov/pubmed/32433600 http://dx.doi.org/10.1038/s41416-020-0867-x |
Ejemplares similares
-
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017) -
FOLFIRINOX in borderline resectable and locally advanced unresectable
pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020) -
Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection
por: Lim, Dong-Hoon, et al.
Publicado: (2023) -
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023) -
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
por: Choi, Yoo Jin, et al.
Publicado: (2021)